ADMA Biologics Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/8/2026)
| Balance Sheet | Total Assets | 624,242,000.00 | ROE | 76.46 % |
| Balance Sheet | Total Equity | 477,320,000.00 | ROA | 23.54 % |
| Cashflow | Capital Expenditures | -22,575,000.00 | P/FCF | 91.02 |
| Cashflow | Free Cash Flow | 27,821,000.00 | – | – |
| Cashflow | Operating Cash Flow | 50,396,000.00 | P/CF | 50.25 |
| Income | Earnings per Share (diluted) | 0.60 | Div. Yield | – |
| Income | Net Income | 146,930,000.00 | P/E | 17.23 |
| Income | Shares Outstanding | 244,905,000.00 | P/B | 5.31 |
| Income | Total Revenue | 510,173,000.00 | P/S | 4.96 |
Ratios calculated on: 10/14/2026
Company Description
ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.admabiologics.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more